Hemoglobinopathies

A team of French researchers used data from their small prospective clinical study to develop a population pharmacokinetics model of hydroxyurea (HU). The authors found that estimated glomerular filtration rate (eGFR) and body weight were determinants of HU kinetics, with lower eGFR or body weight associated with a higher HU area under the curve. They recommend that HU dose be adjusted based on eGFR and that pharmacokinetics of HU be monitored through eGFR and body weight, “which together account for 47% of [HU pharmacokinetics] variability.”